PRN 1008

Drug Profile

PRN 1008

Alternative Names: PRN-1008

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Principia Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
  • Phase I Autoimmune disorders

Most Recent Events

  • 21 Feb 2018 Principia Biopharma plans a phase I pharmacokinetics study of two formulations of PRN 1008 in healthy volunteers in Australia in February 2018 (ACTRN12618000249257p)
  • 13 Dec 2017 Phase-II clinical trials in Idiopathic thrombocytopenic purpura (PO) (Principia Biopharma pipeline, March 2018)
  • 13 Dec 2017 Pharmacodynamics data from a preclinical trial in Autoimmune disorders presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top